1. Pink Sheet

Pricing Disclosure Demands During Medicare Negotiation Process May Be Fodder For Lawsuits

 
• By Cathy Kelly

Regulatory attorneys suggest different issues that might form the basis of manufacturer-sponsored litigation against the Centers for Medicare and Medicaid Services.

IRA Attempts To Head Off Legal Action But Lawsuits Probably Inevitable • Source: Shutterstock

The Inflation Reduction Act specifically bars legal action against many aspects of the Medicare price negotiation program it establishes. But regulatory attorneys agree industry-sponsored legal action against the implementation of the Medicare price negotiation program is inevitable.

The law mandates there can be no “administrative or judicial review” of the Centers for Medicare and Medicaid Services’ selection...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

EMA Explores Supporting Drug Development For High Unmet Need Disorder Scleroderma

 
• By Neena Brizmohun

While treatments for scleroderma are in development, none are approved for the condition that is associated with high morbidity and mortality. The European Medicines Agency says guidance on how to design development programs for the disorder is needed.

EMA Nod For First MASH Drug Rezdiffra, Cell Therapy Zemcelpro And 11 Others

 
• By Eliza Slawther

Madrigal Pharmaceuticals’ Rezdiffra is on track to become the first medicine approved in the EU for non-cirrhotic metabolic dysfunction-associated steatohepatitis after the European Medicines Agency recommended that it be granted conditional marketing authorization.

BIO Notebook: Policy Uncertainty Constraining Dealmaking

 
• By Mandy Jackson and Joseph Haas

Highlights from Day Four of the BIO International Convention include policy concerns helping constrain dealmaking, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.